Recent breakthroughs in CRISPR gene-editing technology include the first personalized CRISPR therapy for a child with a rare metabolic disorder, achieving successful treatment in 2025. Prime editing has shown promise in clinical trials, enhancing immune-cell function in a teenager. Novel adenine base editors offer superior precision, matching Cas9 efficiency. CRISPR-TO, a modified Cas13 system, targets RNA in neurons for repair, showing potential for neurological diseases. CRISPR has been used to remove extra chromosomes in Down syndrome cells, restoring function. Additionally, a new Cas12a tool enables simultaneous assessment of multiple genetic interactions, advancing disease modeling. These innovations enhance precision, safety, and applicability in treating genetic diseases, cancer, and neurological conditions.